What exactly did Leerink do on March 09, 2026?

On March 09, 2026 Leerink Partners maintained its **Market Perform** rating on BioMarin. The note emphasized a cautious view on Voxzogo and did not issue a new price target. This is the core update captured in the BMRN analyst rating.

Does the maintained rating mean a BMRN downgrade or upgrade?

A maintained Market Perform is neither an upgrade nor a downgrade. It leaves the BMRN analyst rating unchanged and signals neutral near-term expectations until clearer commercial data arrives.

Are there any new price targets from Leerink or other firms?

Leerink did not publish a new price target with the March 09, 2026 note. The BMRN analyst rating update therefore lacks a fresh target, so investors must rely on existing targets and upcoming guidance for valuation context.

How should investors use this BMRN analyst rating in decisions?

Treat the maintained Market Perform as a cue to monitor Voxzogo uptake and financial updates. Combine the BMRN analyst rating with your risk tolerance, the Meyka B+ grade, and near-term catalysts before changing position sizes.

Analyst Ratings

Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026

ByHuzaifa Zahoor March 10, 2026

Leerink Partners on March 09, 2026 maintained its Market Perform rating on BioMarin Pharmaceutical Inc. (BMRN). The BMRN analyst rating reflects Leerink’s continued caution about commercial rollout and uptake for Voxzogo, signaling steady but guarded expectations. Leerink did not publish a new price target in the note, and the firm reiterated a cautious tone on near-term revenue drivers. BioMarin’s market capitalization stands at $11,706,701,010, and investors should read this maintained rating as a call for selective patience rather than a directional buy or sell signal. Meyka AI rates BMRN with a grade of B+.